Nanobiotix shares, last in the SBF 120, fall 3% despite a 32% gain over one month

The stock slips back below the week's high but keeps its lead over its short-term averages

The Nanobiotix stock is down 3.1% at €28.12, making it the largest decline in the SBF 120, which is up 0.28% at the same time.

The pullback remains modest given the recent trajectory: the share price still shows a 32.4% gain over one month and 10.1% over seven days. It remains 4.5% above its MM50 (€26.92) and 8.2% above its MM20 (€25.98), while the MM200, at €29.64, sits 5.1% above the share price. This long-term average has not been regained since the October slide, and resistance at €30.36 lies just above.

Over three months, the stock is still down 13.5%, which places the monthly gain within a rebound movement rather than an established trend.

Two conferences in London on 16 and 17 November for the biotech's management

The company's next scheduled event is on the agenda: in its press release of 9 November, Nanobiotix announced that its executives will speak at the conferences organized by Jefferies and UBS in London on 16 and 17 November.

On the fundamentals, the company published its first-half results on 24 September 2026 and stated at the time that it had sufficient liquidity to cover its obligations for at least twelve months, with cash of €110.9 million expected to fund its operations until 2029.

Nanobiotix is listed in Paris (ordinary share, PEA-eligible) and on the Nasdaq (ADS, not PEA-eligible), at a ratio of one ADS per share: the two lines represent the same security. The €30.36 level, already mentioned, remains the threshold to clear in order to regain its resistance zone.